"Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study." Nutrients
and in the Arabidopsis TAIR database ( under the following accession numbers: ACT2 (AT3G18780), AtMORF2 (AT2G33430), FRK1 (AT2G19190), PR1 (AT2G14610), PR4 (AT3G04720), PAD3 (AT3G26830), ICS1 (AT1G74710), SARD1 (AT1G73805), MKK5 (AT3G21220), LHCB1.2 (AT1G29910), PsbA (ATCG00020), PETE (AT1G20340), PR2 (AT3G57260), and PAD4 (AT3G52430)
These alternatives can provide similar benefits without the potential adverse effects on glutathione levels
In the SURPASS-2 diabetes trial, an open-label 40-week study randomised 1,879 patients with type 2 diabetes to tirzepatide 5, 10, or 15 mg or to semaglutide 1 mg
doi:10.1046/j.1365-2036.2002.01151.x 13Lichtenstein GR, Kamm MA, Boddu P, et al
When GSH does its job, it can get used up and turn into a form called GSSG (oxidised glutathione), which doesnt work the same way